Leapfrog Bio

Executive Summary

Leapfrog Bio is a San Diego-based precision oncology company developing targeted therapies for cancers driven by loss-of-function mutations, a class of genetic alterations that are currently undruggable with conventional approaches. Founded in 2021, the company leverages its proprietary OncoSLX platform to identify and retarget de-risked, clinical-stage small molecule drugs to specific genetic vulnerabilities in tumors. This strategy aims to expand the therapeutic utility of existing drugs to new patient populations with high unmet need. Leapfrog Bio is currently in Phase 1 clinical development, and its platform-based approach could potentially accelerate the path to clinic for multiple programs. The company's focus on precision medicine and repurposing established compounds may reduce development risk and time to market, though it remains an early-stage private entity with limited public data.

Upcoming Catalysts (preview)

• Q1 2027Initial Phase 1 Safety and Efficacy Data40% success
• Q4 2026First IND Filing for Second Program60% success
• Q2 2027Partnership or Licensing Agreement30% success